Immunotherapy News and Research

Latest Immunotherapy News and Research

Lytix Biopharma, KAEL-GemVax initiate treatment in LTX-315/GV1001 combination anti-cancer vaccine trial

The Norwegian biopharmaceutical company Lytix Biopharma and the Korean biotechnology company KAEL-GemVax announced today the successful first treatment in the study of a combination of LTX-315 and GV1001 as anti-cancer vaccine therapy.

7 Dec 2010

Xencor, MorphoSys initiate XmAb5574 Phase 1 study in CLL

Xencor, Inc. and MorphoSys AG announced today that they have initiated Phase 1 testing for XmAb®5574 (MOR208), and the first patient has been dosed. XmAb5574 (MOR208) is a potent monoclonal anti-CD19 antibody to which MorphoSys recently gained worldwide access via an exclusive license and collaboration agreement with Xencor.

2 Dec 2010

Tolerx enters collaborative research agreement with Cancer Research Institute

Tolerx, Inc., a biopharmaceutical company developing novel therapies by modulating T cell activity, and the Cancer Vaccine Acceleration Fund (CVAF) a nonprofit program of the Cancer Research Institute established in partnership with the Ludwig Institute for Cancer Research today announced they entered into a collaborative research agreement to support development of Tolerx's drug candidate, TRX518, a monoclonal antibody designed to enhance the immune system by enabling T cells to more effectively attack cancer cells.

2 Dec 2010

Physician-scientists enroll patients with NSCLC cancer in MAGE-A3 Phase III trial

An experimental immunotherapy may someday become the newest weapon against lung cancer. Physician-scientists from Weill Cornell Medical College and Columbia University Medical Center are enrolling patients with non-small cell lung cancer (NSCLC) at NewYork-Presbyterian Hospital as part of an ongoing Phase III trial.

1 Dec 2010

Argos commences dosing in Arcelis personalized immunotherapy Phase 2b clinical trial for HIV

Argos Therapeutics today announced that it has initiated dosing of patients in a Phase 2b clinical trial of its Arcelis™ personalized immunotherapy for the treatment of HIV patients, AGS-004.

30 Nov 2010

DTRA presents Outstanding Scientific Achievement award to Aduro BioTech

Aduro BioTech, a clinical-stage immunotherapy company, is pleased to announce the "Outstanding Scientific Achievement" award from the Defense Threat Reduction Agency. The award was presented at the 2010 Chemical and Biological Defense Science and Technology Conference in Orlando, Florida to Dr. Justin Skoble, Associate Director, Biodefense and Process Development at Aduro BioTech.

30 Nov 2010

USPTO awards Immunitor key patent for viral vaccine

Immune Network Ltd., advises that its potential acquisition, Immunitor USA Inc., has been issued a key patent by the U.S. Patent and Trademark Office (USPTO).

29 Nov 2010

HAL Allergy files MAA for PURETHAL Mites and SUBLIVAC FIX products at Paul-Ehrlich-Institute

HAL Allergy today announced that it has filed marketing authorization applications (MAA) for PURETHAL(R) Mites and SUBLIVAC(R) FIX Grasses, Trees, and Mites (incl. homologous group products) at the Paul-Ehrlich-Institute, the regulatory authority in Germany.

29 Nov 2010

Use of aspirin and statins can reduce depression: Study

A study that appears in the current issue of Psychotherapy and Psychosomatics addresses the association between use of aspirin and statins and the risk of major depression.

25 Nov 2010

Advaxis initiates ADXS11-001 clinical trial for cervix cancer

Advaxis, Inc., the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company, has begun dosing patients in its 110 patient clinical trial of ADXS11-001 for the treatment of cervix cancer in women for whom cytotoxic treatment has failed.

24 Nov 2010

CEL-SCI holds clinical investigator meeting for Multikine Phase III clinical trial in head, neck cancer

CEL-SCI Corporation today announced that the Company held a clinical investigator meeting during the week of November 14th for its Phase III clinical trial of Multikine®, the Company's flagship immunotherapy developed as a first-line standard of care in treating head and neck cancer.

23 Nov 2010

Celldex presents ACT III Phase 2 clinical trial data for glioblastoma multiforme at SNO Meeting

Celldex Therapeutics, Inc., today announced the presentation of complete data for the primary endpoint of ACT III, a multi-center, single arm, Phase 2 clinical trial of rindopepimut (CDX-110) in patients with newly diagnosed glioblastoma multiforme (GBM).

21 Nov 2010

Transplantation of gene-modified hematopoietic stem cells eliminates cancer: Research

A potent anti-tumor gene introduced into mice with metastatic melanoma has resulted in permanent immune reconfiguration and produced a complete remission of their cancer, according to an article to be published in the December 2010 issue of the Journal of Clinical Investigation.

19 Nov 2010

Circassia announces positive result from phase II T-cell vaccine study for house dust mite allergy

Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced successful clinical results from a phase II study of its T-cell vaccine targeting house dust mite allergy.

18 Nov 2010

Food allergies may lead to 'kissing' allergies

Even brushing your teeth or waiting hours after eating may not prevent some partners of people with food and medicine allergies from triggering an allergic reaction through a kiss, according to allergists at the annual scientific meeting of the American College of Allergy, Asthma and Immunology (ACAAI) in Phoenix, Nov.11-16.

17 Nov 2010

Children's Hospital pediatric immunologist collaborates with European gene therapy researchers to study WAS syndrome

A pediatric immunologist at The Children's Hospital of Philadelphia collaborated with European gene therapy researchers who achieved marked clinical improvements in two young children with Wiskott-Aldrich syndrome, a very rare but often severe immunodeficiency disorder.

16 Nov 2010

Millions of Americans suffer unnecessarily with itchy, gritty, watery eyes, say allergists

Millions of Americans suffer unnecessarily with itchy, gritty, watery eyes, according to allergists at the annual scientific meeting of the American College of Allergy, Asthma and Immunology in Phoenix, Nov. 11-16. The underdiagnosis, undertreatment and self-treatment of eye allergies may seriously diminish quality of life, allergists say.

16 Nov 2010

Immunitor completes V5 Phase IIb imm01 clinical trial enrollment for TB

Immune Network Ltd., advises that its potential acquisition, Immunitor USA Inc., has announced the completion of enrollment in its Phase IIb imm01 clinical trial of V5 in tuberculosis.

15 Nov 2010

SLIT immunotherapy effective for long-term remission of bothersome allergy symptoms

Antihistamines and nasal steroids offer good short-term options for people with mild allergy, but allergy immunotherapy, better known as "allergy shots," is a preferred method for achieving long term remission of more bothersome allergy symptoms. Allergists mark the 100th anniversary of immunotherapy and present the latest advances at the American College of Allergy, Asthma and Immunology (ACAAI) annual scientific meeting in Phoenix, Nov. 11-16.

12 Nov 2010

Oligomerix receives SBIR Phase II grant to develop drugs for Alzheimer’s disease

Oligomerix, Inc. today announced the receipt of a two-year Small Business Innovation Research (SBIR) Phase II grant for $1.6M from the National Institute on Aging, National Institutes of Health (NIH), for a program to discover small molecules and antibodies targeting tau protein oligomers in the development of disease modifying therapeutics for Alzheimer's disease.

12 Nov 2010

Immunotherapy News and Research

Latest Immunotherapy News and Research

Lytix Biopharma, KAEL-GemVax initiate treatment in LTX-315/GV1001 combination anti-cancer vaccine trial

Xencor, MorphoSys initiate XmAb5574 Phase 1 study in CLL

Tolerx enters collaborative research agreement with Cancer Research Institute

Physician-scientists enroll patients with NSCLC cancer in MAGE-A3 Phase III trial

Argos commences dosing in Arcelis personalized immunotherapy Phase 2b clinical trial for HIV

DTRA presents Outstanding Scientific Achievement award to Aduro BioTech

USPTO awards Immunitor key patent for viral vaccine

HAL Allergy files MAA for PURETHAL Mites and SUBLIVAC FIX products at Paul-Ehrlich-Institute

Use of aspirin and statins can reduce depression: Study

Advaxis initiates ADXS11-001 clinical trial for cervix cancer

CEL-SCI holds clinical investigator meeting for Multikine Phase III clinical trial in head, neck cancer

Celldex presents ACT III Phase 2 clinical trial data for glioblastoma multiforme at SNO Meeting

Transplantation of gene-modified hematopoietic stem cells eliminates cancer: Research

Circassia announces positive result from phase II T-cell vaccine study for house dust mite allergy

Food allergies may lead to 'kissing' allergies

Children's Hospital pediatric immunologist collaborates with European gene therapy researchers to study WAS syndrome

Millions of Americans suffer unnecessarily with itchy, gritty, watery eyes, say allergists

Immunitor completes V5 Phase IIb imm01 clinical trial enrollment for TB

SLIT immunotherapy effective for long-term remission of bothersome allergy symptoms

Oligomerix receives SBIR Phase II grant to develop drugs for Alzheimer’s disease

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Immunotherapy News and Research

Latest Immunotherapy News and Research

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Newsletters you may be interested in